92 related articles for article (PubMed ID: 769959)
1. Adriamycin (NSC-123127) plus 5-fluorouracil (NSC-19893): a phase I study.
Tranum BL; Stephens RL; Lehane DE; Hoogstraten B; Lane M; Haut A
Cancer Chemother Rep; 1975; 59(6):1163-5. PubMed ID: 769959
[No Abstract] [Full Text] [Related]
2. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors.
Stephens RL; Hoogstraten B
Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901
[No Abstract] [Full Text] [Related]
3. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
Eagan RT; Utz DC; Myers RP; Furlow WL
Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
Eagan RT; Hahn RG; Myers RP
Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
[No Abstract] [Full Text] [Related]
5. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG
Cancer Chemother Rep; 1974; 58(6):877-82. PubMed ID: 4614896
[No Abstract] [Full Text] [Related]
6. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
[No Abstract] [Full Text] [Related]
7. Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
Lowitz BB
Cancer Treat Rep; 1976 May; 60(5):623-4. PubMed ID: 991153
[No Abstract] [Full Text] [Related]
8. Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer.
DeWys WD
Cancer Chemother Rep; 1975; 59(1):215-7. PubMed ID: 1093668
[No Abstract] [Full Text] [Related]
9. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
Baker LH; Saiki JH; Jones SE; Hewlett JS; Brownlee RW; Stephens RL; Vaitkevicius VK
Cancer Treat Rep; 1977 Nov; 61(8):1595-7. PubMed ID: 200359
[No Abstract] [Full Text] [Related]
10. Preliminary trials with a combination of adriamycin (NSC-123127) and bleomycin (NSC-125066) in adult malignancies.
Tormey DC; Bergevin P; Blom J; Petty W
Cancer Chemother Rep; 1973; 57(4):413-8. PubMed ID: 4128422
[No Abstract] [Full Text] [Related]
11. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.
Brambilla C; De Lena M; Bonadonna G
Cancer Chemother Rep; 1974; 58(2):251-3. PubMed ID: 4598244
[No Abstract] [Full Text] [Related]
13. Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Ellerby RA; Davis HL; Ansfield FJ; Ramirez G
Cancer; 1974 Oct; 34(4):1005-10. PubMed ID: 4607883
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037).
Einhorn LH; Livingston RB; Gottlieb JA
Cancer Chemother Rep; 1973; 57(4):437-45. PubMed ID: 4586951
[No Abstract] [Full Text] [Related]
15. Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors.
Evans AE; Baehner RL; Chard RL; Leikin SL; Pang EM; Pierce M
Cancer Chemother Rep; 1974; 58(5 Pt 1):671-6. PubMed ID: 4371948
[No Abstract] [Full Text] [Related]
16. [Chemotherapy schedule for the management of metastasizing gastric cancer. Methotrexate, adriamycin and 5-fluorouracil].
Klein HO; Wickramanayake PD; Dieterle F; Mohr R; Oerkermann H; Brock J; Beyer D; Gross R
Dtsch Med Wochenschr; 1982 Nov; 107(45):1708-12. PubMed ID: 7140549
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma.
Umsawasdi T; Chainuvati T; Hitannant S; Nilprabhassorn P; Viranuvatti V
Cancer Chemother Rep; 1975; 59(6):1167-9. PubMed ID: 177190
[No Abstract] [Full Text] [Related]
18. Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Rees GJ; Bugaighis A; Anderson G
Br J Dis Chest; 1975 Jul; 69():199-206. PubMed ID: 1201186
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
Abeloff MD; Ettinger DS
Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
Haller DG; Woolley PV; Macdonald JS; Smith LF; Schein PS
Cancer Treat Rep; 1978 Apr; 62(4):563-5. PubMed ID: 350394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
